Notify me when Pontifax Management 4 G.P. (2015) Ltd. files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| CLYM | Climb Bio, Inc. | Common Stock, par value $0.0001 per share | 7.7% | $12,911,822 | 5,206,380 | Pontifax VI G.P. L.P. | 27 Jun 2024 | ||
| LB Pharmaceuticals Inc | Common Stock, $0.0001 par value per share | 6.3% | 1,411,681 | Pontifax Management 4 G.P. (2015) Ltd. | 12 Sep 2025 | ||||
| KROS | Keros Therapeutics, Inc. | Common Stock, Par Value $0.0001 Per Share | 0% | $0 | -$75,735,576 | 0 | -100% | Pontifax Management 4 GP (2015) Ltd. | 15 Oct 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|